Albumin, a type of protein found in blood plasma, can play a significant role in the delivery of the chemotherapy drug Paclitaxel. Paclitaxel is a widely used anti-cancer drug, primarily used to treat ovarian and breast cancers. However, Paclitaxel has poor water solubility, which can limit its effectiveness. This is where albumin comes in.

Albumin can bind with Paclitaxel, forming a nano-particle complex, which enhances the drug's solubility and stability, allowing for improved delivery to cancer cells. This albumin-bound Paclitaxel is marketed under the brand name Abraxane.

The albumin-Paclitaxel complex is taken up by cancer cells through a process known as albumin receptor-mediated endocytosis. Once inside the cancer cell, the Paclitaxel is released from the albumin, exerting its anti-cancer effects.

This albumin-assisted delivery method has several advantages over traditional Paclitaxel delivery. It allows for higher doses of the drug to be administered, enhancing its efficacy. Moreover, it reduces the need for potentially toxic solvents used in traditional Paclitaxel formulations, thereby reducing side effects.

In conclusion, albumin plays a crucial role in enhancing the delivery and efficacy of Paclitaxel, a widely used anti-cancer drug.

Sources:
1. [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/abraxane)
2. National Center for Biotechnology Information. PubChem Compound Summary for CID 64276, Paclitaxel. Last updated on December 10, 2020.
3. National Center for Biotechnology Information. PubChem Compound Summary for CID 121357625, Human Serum Albumin. Last updated on December 10, 2020.
4. Desai, N. K., Kulkarni, P. V., & Bodas, R. W. (2016). Paclitaxel: a comprehensive review. Journal of chemotherapy, 28(5), 325–333. [Online]. Available at: <https://onlinelibrary.wiley.com/doi/full/10.1111/jct.12542>.